ClinicalTrials.gg
Active, not recruitingNCT07128316Updated Aug 18, 2025

LASIK Using Contoura With Phorcides vs. iDesign

An interventional study of Contoura Topolyzer with Phorcides and iDesign in Myopia and Astigmatism, sponsored by 59th Medical Wing. Active, not recruiting at 1 site in United States. Open to participants aged 21 Years to 50 Years. Per ClinicalTrials.gov, last updated 2025-08-18.

Sponsored by 59th Medical Wing · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as active, not recruiting.
  • Registered 1 year 11 months after the study started (first participant enrolled Sep 2023, registered Aug 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
63
Allocation
Randomized
Ages
21 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 342 studies in Myopia with a site in United States — 27 open to participants now, 44 under way, 3 of them phase 3. Myopia · United States.

Planned enrollment
164th of 294
63 · median 68
Started
2023
with 30 others
No phase
243 of 342
16 open now
Primary completion
2025-12
later than 5 of 43 live
Registered
321st of 342
by date

Among the 342 studies in Myopia with a site in United States, this one is the 164th largest by planned enrollment of the 294 interventional ones that give a count, is one of 31 that started in 2023, is one of 243 with no phase, reaches primary completion later than 5 of the 43 other live ones, and was the 321st registered.

Myopia

1,166 studies on the registry are indexed under Myopia; 228 are open to participants now.

Browse Myopia studies →

Open to participants now

27 of the 342 studies in Myopia with a site in United States are open now. Recruiting first, the newest first:

22 more — sign in →

All 27 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 124 Myopia studies recruiting now, 20 (16%) set no upper age limit and 103 (83%) stop at 75 or younger; 85 take children under 18; 53 take healthy volunteers.

This study: 21 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 342 studies in Myopia with a site in United States, or all of them as a file.
02

Study summary

Participants will undergo LASIK using Contoura with Phorcides calculation on one eye and LASIK using iDesign calculation on the contralateral eye to correct myopia.

Read the detailed description

Once consented to participate in the study, subjects will have a comprehensive ocular examination to determine eligibility to undergo LASIK using Contoura with Phorcides calculation on one eye and LASIK using iDesign calculation on the contralateral eye to correct myopia. The study objective is to compare the 6-month visual outcomes (i.e., visual acuity, contract sensitivity, high order aberrations), quality of vision (i.e., double vision, glare, starburst, halos, etc.) and dry eye symptoms of patients undergoing contralateral LASIK using Contoura with Phorcides calculation vs. LASIK using iDesign calculation. Surgical treatment will be randomized so there is a 50% chance to receive LASIK using Contoura with Phorcides vs LASIK using iDesign calculation on the contralateral eye. Subjects will receive standard of care topical ophthalmic antibiotic and steroid drops. This will be a prospective randomized double blind contralateral study. The patient and the staff doing the post-op evaluations will be blinded to which eye received which treatment.

03

Conditions studied

  • Myopia
  • Astigmatism
04

Who can participate

Ages eligible
21 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and Females between the ages of 21 and 50
  • Nearsightedness between -2.00 diopters and -8.00 diopters
  • Have similar levels of nearsightedness in each eye (1.5D of difference between eyes)
  • Less than or equal to 3.00 diopters of astigmatism
  • Have similar levels of astigmatism in each eye (0.75D of difference between eyes)
  • Total spherical equivalent (SE) of no more than -9.0 D
  • Tricare Prime or Tricare Select Beneficiary
  • Residing within 60 miles radius from Lackland AFB

Exclusion criteria

Exclusion Criteria:

  • Subjects with corneal abnormal findings including signs of keratoconus, keratoconus suspect, abnormal corneal topography, epithelial basement membrane disease, pellucid marginal degeneration, corneal degenerations, progressive and unstable myopia, irregular or unstable corneal mires on central keratometry images, and patients whose corneal thickness would cause anticipated treatment would violate the posterior 250 microns of corneal stroma from the corneal endothelium.
  • Subjects with any ocular disease such as advanced/uncontrolled glaucoma, severe dry eye, active eye infection or inflammation, recent herpes eye infection or problems resulting from past infection.
  • Subjects with active collagen vascular, connective tissue, or immunodeficiency diseases
  • Pregnant or nursing females
  • Systemic disease likely to affect wound healing, such as diabetes and severe atopy
  • Taking the medication Isotretinoin (Accutane) or antimetabolites for any medical condition
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
63 participants (estimated)

Study arms

  • Active comparator
    LASIK using Contoura with Phorcides

    Alcon VISX Star S4 IR LASIK ablation calculation using Contoura with Phorcides

    Device: Contoura Topolyzer with Phorcides

  • Active comparator
    LASIK using iDesign

    Alcon VISX Star S4 IR LASIK ablation calculation using iDesign Refractive Studio 2.0

    Device: iDesign

Interventions

  • DeviceContoura Topolyzer with Phorcides

    LASIK calculated ablation using Contoura Topolyzer with Phorcides

  • DeviceiDesign

    LASIK calculated ablation using iDesign Refractive Studio 2.0

06

What researchers measure

Primary outcomes

  1. Percentage of eyes with Uncorrected Visual Acuity of 20/16 or better at 6-month Post-Op

    Post-operative uncorrected visual acuity of 20/16 or better measure with ETDRS chart; unit = percentage eyes with Uncorrected Visual Acuity.

    Time frame: 6-month Post-Op

Secondary outcomes

  1. Change in high contrast visual acuity at 6-month Post-Op

    Change in the mean uncorrected visual acuity (unit = logMAR) measure with ETDRS chart from baseline (pre-op) at 6 months post-op.

    Time frame: Change from baseline (pre-op) to 6-month Post-Op

  2. Change in refractive error at 6-month Post-Op

    Change in the mean refractive error measure with phoropter (unit = diopters) from baseline (pre-op) at 6 months post-op.

    Time frame: Change from baseline (pre-op) to 6-month Post-Op

Other outcomes

  1. Change in low contrast visual acuity at 6-month Post-Op

    Change in the mean low contrast visual acuity (unit = logMAR) measure with ETDRS 5% chart from baseline (pre-op) at 6 months post-op.

    Time frame: Change from baseline (pre-op) to 6-month Post-Op

  2. Change in higher order aberrations at 6-month Post-Op

    Change in the mean higher order aberrations (unit = root mean square) measure with iDesign 2.0 Refractive Studio from baseline (pre-op) at 6 months post-op.

    Time frame: Change from baseline (pre-op) to 6-month Post-Op

  3. Change in mean score Patient-Reported Outcomes with LASIK Symptoms and Satisfaction (PROWL-SS) Questionnaire at 6-month Post-Op

    The PROWL-SS is a validated tool to assess self-reported symptoms and satisfaction after refractive surgery. Possible Satisfaction Score ranges from 1 (completely satisfied) to 6 (completely dissatisfied). Lower value indicates higher satisfaction. Possible Symptoms Score ranges from 1 (extremely bothersome) to 5 (not at all bothersome). Lower value indicates worse symptoms.

    Time frame: Change from baseline (pre-op) to 6-month Post-Op

  4. Change in mean score Standard Patient Evaluation of Eye Dryness (SPEED) questionnaire at 6-month Post-Op

    The SPEED is a validated tool to assess self-reported dry eye symptoms. Possible dry eye symptoms score ranges from 0 (never) to 3 (Constant). Higher value indicates worse dry eye symptoms.

    Time frame: Change from baseline (pre-op) to 6-month Post-Op

07

Study locations

1 site
08

References and documents

Publications

  • Dudenhoefer NE, Rodgers SB, Evangelista CB, Legault GL, Chen SS, Kohler PD, Capo-Aponte JE. Comparison of clinical and patient-reported outcomes of contralateral topography-guided vs wavefront-guided LASIK. J Cataract Refract Surg. 2026 Jul 1;52(7):641-649. doi: 10.1097/j.jcrs.0000000000001905. PubMed 41665909 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Dec 2025, 27 months after the start.

Of 202 non-industry interventional studies with no phase under Myopia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 44. This study's planned 27 months is close to that.

Counting every sponsor, half of 438 studies reached it within 14 months; a quarter within 3 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2025
First posted
Aug 18, 2025
StartActual
Sep 11, 2023
Primary completionEst.
Dec 15, 2025
CompletionEst.
Dec 15, 2025
Last update
Aug 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07128316
Lead sponsor
59th Medical Wing
Responsible party
Sponsor
First posted
Aug 18, 2025
Start date
Sep 11, 2023
Primary completion
Dec 15, 2025 (estimated)
Completion
Dec 15, 2025 (estimated)
Last update
Aug 18, 2025

Study contacts

Samantha B Rodgers, MD
principal investigator · 59th Medical Wing

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion